WO2021074176A1
|
|
Cradle for a medical device
|
WO2021076556A1
|
|
Method and system for providing interactive medical guideline
|
WO2021080804A1
|
|
Machine-learning techniques for prediction of future visual acuity
|
WO2021069504A1
|
|
Drug dosage determination devices and methods
|
WO2021063938A1
|
|
Means and methods for assessing spinal muscular atrophy (sma)
|
WO2021063937A1
|
|
Means and methods for assessing huntington´s disease (hd)
|
WO2021063935A1
|
|
Prediction of disease status
|
WO2021063905A1
|
|
A holder for a medical device
|
WO2021063936A1
|
|
Means and methods for assessing multiple sclerosis (ms)
|
WO2021063852A1
|
|
Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
|
WO2021063856A1
|
|
Substituted 3,4-dihydroquinazoline for the treatment and prophylaxis of hepatitis b virus infection
|
WO2021058132A1
|
|
Cation chromatography using predicted elution buffer salt concentration
|
WO2021058456A1
|
|
Interface for automated fluid injection
|
US2021094972A1
|
|
Heterocyclic compounds
|
US2021094973A1
|
|
Heterocyclic compounds
|
WO2021058443A1
|
|
Fluorescent probes for monoacylglycerol lipase (magl)
|
US2021107921A1
|
|
Heterocyclic compounds
|
WO2021053126A1
|
|
Method of treating hbv infection using a core protein allosteric modulator
|
WO2021053100A1
|
|
Techniques for checking a validity of a mass axis calibration of a mass spectrometer of an analyzer system
|
JP2021006540A
|
|
Galactoengineered immunoglobulin 1 antibodies
|